Sherlock Biosciences

Executive Summary

Sherlock Biosciences, founded in 2019 and headquartered in Cambridge, Massachusetts, is a private biotechnology company developing next-generation molecular diagnostics. Leveraging its proprietary CRISPR-based platform, the company aims to deliver rapid, accurate, and accessible diagnostic solutions for infectious diseases, oncology, and other health conditions. By combining the precision of CRISPR with innovative assay design, Sherlock's technology enables point-of-care testing that can democratize access to critical health information. While still in early stages, the company has positioned itself to address unmet needs in decentralized diagnostics, potentially disrupting traditional lab-based testing models. Its focus on speed and accuracy aligns with global trends toward personalized medicine and pandemic preparedness, though commercialization progress remains limited.

Upcoming Catalysts (preview)

• 2027FDA Emergency Use Authorization or Clearance for CRISPR-based Diagnostic40% success
• 2026Strategic Partnership or Licensing Deal with Major Diagnostic Company50% success
• 2026Series B or Later-Stage Funding Round to Advance Clinical Trials60% success